Fed Circuit overturns Apotex’s PTAB victory
The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.
BGI counter sues Illumina for patent infringement
A US subsidiary of Chinese genome sequencing company BGI has filed a patent infringement counterclaim against Illumina.
US biotech licenses antibody from Takeda for new kidney drugs
Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 antibody from Japanese pharmaceutical manufacturer Takeda.
Novartis and Microsoft to collaborate on AI in medicine
Novartis has teamed with Microsoft to launch a new artificial intelligence innovation lab, which it says has the potential to “transform” and “reimagine” medicine.
USPTO grants new CRISPR-Cas9 patent to University of California
The US Patent and Trademark Office (USPTO) has granted a new CRISPR-Cas9 patent to the University of California (UC), the University of Vienna and Emmanuelle Charpentier, marking the fifth consecutive week that the USPTO has approved a new patent in their CRISPR portfolio.
Bausch targets Sandoz over IBS generic
Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan, Bausch’s irritable bowel syndrome drug.
Abbott sued for patent infringement over infant probiotic
Evolve BioSystems and the University of California have jointly sued Abbott Laboratories for patent infringement over a soon-to-be-launched probiotic product.
FDA and DEA warn over sale of misbranded opioid drugs
The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.
Taiwanese firm accuses Pacific Biosciences of infringing sequencing tech
Taiwan-based Personal Genomics Taiwan has taken gene-sequencing rival Pacific Biosciences to court in the US, over alleged patent infringement.
Drug-to-market cost falls to under $2bn in five years
Bringing a drug to market is costing companies under $2 billion for the first time in five years, according to a report from IP service provider Clarivate Analytics.
